|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
Life sciences CEOs are making decisive moves to secure long-term growth, and the message is clear: standing still is not an option. Findings from the KPMG 2025 CEO Outlook survey show leaders are strategically investing in AI, talent, and operational agility – choosing to accelerate rather than retreat.
|
|
 |
|
Low bioavailability due to poor API solubility is one of the major challenges to be overcome when developing oral dosage form drug products. An effective way of addressing this problem is to transform low solubility APIs into amorphous solid dispersions (ASDs) and can often be achieved via hot melt extrusion (HME).
|
|
 |
|
ABITEC is excited to present its latest excipient, CAPMUL GDO, Glycerol Dioleate. CAPMUL GDO is a high-purity, highly versatile functional lipid
|
|
|
|
|
|
|
|
|
John Tomtishen says amid shifting FDA priorities as well as developing geopolitical considerations, US companies are entering a new regulatory era, one that will define how CGTs are scaled, distributed, and delivered domestically.
|
|
|
Cindy H. Dubin speaks with several companies and highlights this innovation and reveals how excipient suppliers are doing their part to ensure a reliable, resilient, and compliance-driven supply chain.
|
|
|
Shaukat Ali, PhD, and Jim Huang, PhD, say as more NCEs are being discovered, the industry is weighing all options for evaluating those molecules in different dosages to improve solubility and oral bioavailability. With requirement for taste-masking of bitter drugs with commercially available ODT excipients, it poses additional challenges for improving taste-masking and performance of molecules for the intended usages.
|
|
|
Andrew Parker, PhD, John McDermott, and Sandeep Kumar, PhD, believe the development of poorly soluble drugs remains a significant challenge in pharmaceutical R&D. However, by adopting an adaptive approach that integrates services from preclinical screening to clinical optimization, developers can achieve significant time- and cost-saving benefits.
|
|
|
|
|
|
|
|
|

Lubrizol Life Science partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and consumer benefits. Along with our best-in-class pharmaceutical excipients, and nutraceutical actives, we offer our expertise, and capabilities to accelerate your innovations to market.
|
|
|
|
|
|
 |
|
In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.
|
|
 |
|
In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.
|
|
|
|
|
|
|
|
 |
|
The biopharmaceutical classification system classifies drugs according to their permeability and solubility. Drugs with poor solubility and/or permeability are class II or IV type drugs, and these require special formulation technologies for solubility enhancement. In the past 25 …
|
|
 |
|
By: Dr. Jens Morgenthaler, General Manager and Dr. Matthias Rischer, Head of Innovation, Losan Pharma GmbH
Introduction
The successful formulation of small molecules is still one of the important challenges of today, especially if these drugs belong to the BioClassificationSystem …
|
|
 |
|
Providing Ideal Protection for Invaluable Drug Products, Including Cell and Gene Therapy Products
Product Introduction of OXYCAPT™
OXYCAPT™ is a multilayer plastic vial and syringe, consisting of three layers made from two types of resins. The drug contact layer and …
|
|
|
|
|
Upcoming eNewsletter Features:
November 5 – Drug Delivery
November 12 – Parenteral Contract Manufacturing
|
|
|
|
|
|
|
|